Supportive Care Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Science & Technology, Sungkyunkwan University, Seoul, Republic of Korea.
Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
J Thorac Oncol. 2022 Jun;17(6):827-837. doi: 10.1016/j.jtho.2022.02.001. Epub 2022 Feb 11.
To report the trends in incidence and survival associated with thymic epithelial tumors (TETs) in Korea.
Data from 1999 to 2017 were obtained from the Korean Central Cancer Registry. Age-standardized incidence rates and average annual percentage changes (AAPCs) were calculated. Net survival (NS) was estimated by the Pohar-Perme method.
Among 5812 patients diagnosed with having TETs, 58.9%, 38.1%, and 3.0% were diagnosed with having thymoma, thymic carcinoma, and thymic neuroendocrine tumor (NET), respectively. Age-standardized incidence rates were 0.50, 0.30, 0.18, and 0.02 per 100,000 for all TETs and the respective subtypes. There was an increase in incidence of all TETs (AAPC = 6.1%) and subtypes: thymoma (AAPC = 5.6%), thymic carcinoma (AAPC = 7.0%), and thymic NET (AAPC = 3.4%). Proportions of patients with thymoma, thymic carcinoma, and thymic NET were 58.9%, 38.1%, and 3.0%, respectively. For thymoma, the relative proportion of distant stage decreased (19.4% in 2005 to 8.8% in 2017) and low-grade WHO subtype (A, AB, B1) increased faster than high-grade WHO type (B2, B3) (AAPC = 19.8% versus 9.6%). For thymoma, the 5-year NS was 82.3%. This increased from 64.3% in 1999 to 2002 to 90.6% in 2013 to 2017. For thymic carcinoma, the 5-year NS was 46.2% and only slightly increased from 39.4% in 1999 to 2002 to 47.9% in 2013 to 2017.
This study indicates a high incidence of TET and its continuous increase in Korea. The proportion of thymic carcinoma was relatively higher than in the United States or Europe. Survival for thymoma improved during the study period, whereas this was not evident for thymic carcinoma or thymic NET.
报告韩国胸腺瘤（TETs）发病和生存趋势。
数据来自 1999 年至 2017 年韩国中央癌症登记处。计算年龄标准化发病率和平均年百分比变化（AAPC）。通过 Pohar-Perme 法估计净生存率（NS）。
在 5812 例诊断为 TETs 的患者中，分别有 58.9%、38.1%和 3.0%被诊断为胸腺瘤、胸腺癌和胸内神经内分泌肿瘤（NET）。所有 TETs 及各亚型的年龄标准化发病率分别为 0.50、0.30、0.18 和 0.02/10 万。所有 TETs（AAPC=6.1%）和亚型的发病率均呈上升趋势：胸腺瘤（AAPC=5.6%）、胸腺癌（AAPC=7.0%）和胸内 NET（AAPC=3.4%）。胸腺瘤、胸腺癌和胸内 NET 的患者比例分别为 58.9%、38.1%和 3.0%。对于胸腺瘤，远处转移期的比例下降（2005 年为 19.4%，2017 年为 8.8%），低级别 WHO 亚型（A、AB、B1）的增长速度快于高级别 WHO 型（B2、B3）（AAPC=19.8%比 9.6%）。胸腺瘤的 5 年 NS 为 82.3%。这一数值从 1999 年至 2002 年的 64.3%增加到 2013 年至 2017 年的 90.6%。对于胸腺癌，5 年 NS 为 46.2%，仅从 1999 年至 2002 年的 39.4%略微增加到 2013 年至 2017 年的 47.9%。
本研究表明，韩国 TET 的发病率较高且呈持续上升趋势。胸腺癌的比例相对高于美国或欧洲。研究期间，胸腺瘤的生存率有所提高，而胸腺癌或胸内 NET 则不然。
